Abou-Bakr Amany A, Eldweny Hany I
Department of Pathology, National Cancer Institute, Cairo University, Egypt.
Ecancermedicalscience. 2013 May 14;7:317. doi: 10.3332/ecancer.2013.317. Print 2013.
Basal-like breast carcinoma (BLBC) has attracted considerable attention over the past few years. It has been suggested that tumours expressing basal markers have a more aggressive clinical behaviour. However, a molecular basis for this disease remains unclear, and it lacks currently used therapeutic targets. Therefore developing a novel treatment strategy is crucial for improving the prognosis. The aim of this study was to characterise the immunohistochemical (IHC) expression of p16 in patients with BLBC compared with non-BLBC.
Eighty-five cases of grade-3 invasive ductal carcinomas not otherwise specified (IDC-NOS) were analyzed. Immunohistochemical stains for oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor type 2 (HER2), cytokeratin (CK) 5/6, epidermal growth factor receptor (EGFR) and p16 were performed. BLBC was defined as ER-, PR-, Her2- and CK5/6+, and/or EGFR+.
Twenty cases were categorised as BLBC versus 65 as non-basal. High mitotic count and presence of necrosis were associated with basal-like phenotype. Distant metastasis developed in 40% of cases of BLBC with frequent spread to brain and lung. p16 had significantly higher expression in the basal subgroup (80% versus 50.8%, P = 0.04). Patients with BLBCs were found to have a lower disease-free survival (DFS) rate (60% versus 70.8%, P = 0.03).
BLBC typically demonstrates a unique profile. p16 is frequently expressed in breast cancers with basal-like phenotype; this suggests that p16 may play a role in the poor prognosis of this tumour, and it may be used in the development of a targeted therapy that will result in improved patient prognostication and outcome.
基底样乳腺癌（BLBC）在过去几年中受到了广泛关注。有研究表明，表达基底标志物的肿瘤具有更具侵袭性的临床行为。然而，这种疾病的分子基础仍不清楚，且缺乏目前可用的治疗靶点。因此，开发新的治疗策略对于改善预后至关重要。本研究的目的是比较BLBC患者与非BLBC患者中p16的免疫组化（IHC）表达情况。
分析了85例未另作特殊说明的3级浸润性导管癌（IDC-NOS）病例。进行了雌激素受体（ER）、孕激素受体（PR）、人表皮生长因子受体2型（HER2）、细胞角蛋白（CK）5/6、表皮生长因子受体（EGFR）和p16的免疫组化染色。BLBC被定义为ER-、PR-、Her2-且CK5/6+和/或EGFR+。
20例被归类为BLBC，65例为非基底样。高有丝分裂计数和坏死的存在与基底样表型相关。40%的BLBC病例发生远处转移，且常转移至脑和肺。p16在基底亚组中的表达明显更高（80%对50.8%，P = 0.04）。发现BLBC患者的无病生存率（DFS）较低（60%对70.8%，P = 0.03）。
BLBC通常表现出独特的特征。p16在具有基底样表型的乳腺癌中频繁表达；这表明p16可能在该肿瘤的不良预后中起作用，并且它可能用于开发靶向治疗，从而改善患者的预后和结局。
